Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems
In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the er...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Chemistry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2022.957572/full |
| _version_ | 1817999508527644672 |
|---|---|
| author | Faranak Hejabi Mohammad Sadegh Abbaszadeh Shirinsadat Taji Andrew O’Neill Fatemeh Farjadian Mohammad Doroudian |
| author_facet | Faranak Hejabi Mohammad Sadegh Abbaszadeh Shirinsadat Taji Andrew O’Neill Fatemeh Farjadian Mohammad Doroudian |
| author_sort | Faranak Hejabi |
| collection | DOAJ |
| description | In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the era of genome editing, the safe and effective delivery of CRISPR/Cas systems represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In addition, there are some challenges in the in vivo delivery to the targeted cells/tissues. Nanotechnology-based drug delivery systems can be employed to overcome this issue. This review discusses different types and forms of CRISPR/Cas systems and the current CRISPR/Cas delivery systems, including non-viral carriers such as liposomes, polymeric, and gold particles. The focus then turns to the viral nanocarriers which have been recently used as a nanocarrier for CRISPR/Cas delivery. |
| first_indexed | 2024-04-14T03:09:50Z |
| format | Article |
| id | doaj.art-d0669481ac64444ca3dfd7a95d0ed635 |
| institution | Directory Open Access Journal |
| issn | 2296-2646 |
| language | English |
| last_indexed | 2024-04-14T03:09:50Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Chemistry |
| spelling | doaj.art-d0669481ac64444ca3dfd7a95d0ed6352022-12-22T02:15:38ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462022-07-011010.3389/fchem.2022.957572957572Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systemsFaranak Hejabi0Mohammad Sadegh Abbaszadeh1Shirinsadat Taji2Andrew O’Neill3Fatemeh Farjadian4Mohammad Doroudian5Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, IranCollege of Art and Science, Syracuse University, Syracuse, NY, United StatesDepartment of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, IranDepartment of Clinical Medicine, Tallaght University Hospital and Trinity College Dublin, Dublin, IrelandPharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IranDepartment of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, IranIn recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the era of genome editing, the safe and effective delivery of CRISPR/Cas systems represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In addition, there are some challenges in the in vivo delivery to the targeted cells/tissues. Nanotechnology-based drug delivery systems can be employed to overcome this issue. This review discusses different types and forms of CRISPR/Cas systems and the current CRISPR/Cas delivery systems, including non-viral carriers such as liposomes, polymeric, and gold particles. The focus then turns to the viral nanocarriers which have been recently used as a nanocarrier for CRISPR/Cas delivery.https://www.frontiersin.org/articles/10.3389/fchem.2022.957572/fullnanocarriersCRISPR/Cas9gene therapynanomedicinenon-viral vector |
| spellingShingle | Faranak Hejabi Mohammad Sadegh Abbaszadeh Shirinsadat Taji Andrew O’Neill Fatemeh Farjadian Mohammad Doroudian Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems Frontiers in Chemistry nanocarriers CRISPR/Cas9 gene therapy nanomedicine non-viral vector |
| title | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
| title_full | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
| title_fullStr | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
| title_full_unstemmed | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
| title_short | Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems |
| title_sort | nanocarriers a novel strategy for the delivery of crispr cas systems |
| topic | nanocarriers CRISPR/Cas9 gene therapy nanomedicine non-viral vector |
| url | https://www.frontiersin.org/articles/10.3389/fchem.2022.957572/full |
| work_keys_str_mv | AT faranakhejabi nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT mohammadsadeghabbaszadeh nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT shirinsadattaji nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT andrewoneill nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT fatemehfarjadian nanocarriersanovelstrategyforthedeliveryofcrisprcassystems AT mohammaddoroudian nanocarriersanovelstrategyforthedeliveryofcrisprcassystems |